{"id":"NCT01890122","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2015-09","completion":"2015-10","firstPosted":"2013-07-01","resultsPosted":"2016-11-28","lastUpdate":"2016-11-28"},"enrollment":647,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR-322; Nesina"]},{"type":"DRUG","name":"Metformin HCl","otherNames":["Glucophage"]},{"type":"DRUG","name":"Alogliptin and Metformin Fixed-Dose Combination (FDC)","otherNames":["Kazano"]},{"type":"DRUG","name":"Alogliptin Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin Placebo","otherNames":[]},{"type":"DRUG","name":"Alogliptin and Metformin FDC Placebo","otherNames":[]}],"arms":[{"label":"Metformin HCl 500 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 12.5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 12.5 mg + Metformin HCl 500 mg FDC","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2 Diabetes Mellitus (T2DM).","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)","timeFrame":"Baseline and Week 26 (or Early termination)","effectByArm":[{"arm":"Metformin HCl 500 mg","deltaMin":-0.32,"sd":1.067},{"arm":"Alogliptin 12.5 mg","deltaMin":-1.23,"sd":0.877},{"arm":"Alogliptin 12.5 mg + Metformin HCl 500 mg FDC","deltaMin":-1.06,"sd":0.97},{"arm":"Placebo","deltaMin":-1.72,"sd":1.024}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.0001"},{"comp":"OG001 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["China","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203414s000lbl.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":161},"commonTop":["Upper respiratory tract infection","Hyperlipidaemia","Protein urine present","Nasopharyngitis","Diarrhoea"]}}